MAPT and Alzheimer disease: These observations are consistent with defects in the selective nuclear envelope permeability seen in induced pluripotent stem cell (iPSC)-derived neurons with IVS10 + 16 and P301L MAPT mutations [19], and in primary neurons treated with high molecular weight Alzheimer’s disease brain fractions containing tau [14].